silica, manganese, magnesium, copper, boron, analgesics, anti-inflammatory agents, methyl-sulfonyl-methane, S-adenosyl-methionine, alpha-lipoic acid, aloe vera extract, antioxidants, anti-infective agents, adjuvants, anthocyanidins, proanthocyanidins, and herbal derivatives, and mixtures thereof.

4. The method of claim 1, wherein said composition has an enteric coating to deliver the composition orally in a controlled release into the gastrointestinal tract.

5. The method of claim 1, wherein the composition further comprises a carrier suitable for oral, rectal, parental, intravenous, topical, transdermal, subcutaneous, and intramuscular administration.

6. The method of claim 1, wherein said inhibitors of nitric oxide synthase include zinc compounds, arginine derivatives, flavoprotein binders, diphenylene iodonium and derivatives thereof, ornithine and derivatives thereof, N-imino-ethyl-L-ornithine, tetracycline, L-canavanine, citrulline, redox dyes, methylene blue, calmodulin binders, trifluoropiperazine, calcinarin, heme binders, tetrahydropterin derivatives, aminoguanidine, depleters of biopterin, methotrexate, nonsteroidal anti-inflammatory agents, sodium salicylate, and mixtures thereof.

7. The method of claim 6, wherein said arginine derivitives include methylated arginines, substituted L-arginine, nitro-arginine, L-N^G-nitroarginine, N^G-monomethyl-L-arginine (NMA), N-nitro-L-arginine methyl ester, N-amino-L-arginine, N-methyl-L-arginine, N^G-monomethyl-L-arginine (L-NMA), L-N^G-monomethylarginine (L-NMMA).

8. A composition for treating arthritis in mammals by administering a therapeutically effective amount of a composition comprising:

a) an inhibitor of nitric oxide production, and

b) an aminosugar.

9. The composition of claim 8, wherein said inhibitors of nitric oxide production comprises nitric oxide synthase inhibitors and nitric oxide scavangers comprising; arginine-based analogues, methylated arginines, substituted L-arginine, nitro-arginine, L-N^G-nitroarginine, N^G-mono-methyl-L-arginine (L-NMMA), N-nitro-L-arginine methyl ester (L-NAME), N-amino-L-arginine, N-methyl-L-arginine, N^G-monomethyl-L-arginine (L-NMA), N^G-nitro-L-arginine (L-NNA), aminoguanidine, 7-nitroindazole, S-ethylisothiourea, S-methylisothiourea, S-methylthiocitriulline, S-ethylthiocitrulline, N-ethylimino-L-ornithine, flavoprotein binders. diphenyleneiodonium and related iodonium derivatives, ornithine and ornithine derivatives; tetracycline; L-canavanine; citrulline; redox dyes, methylene blue; calmodulin binders, trifluoropiperazine and calcinarin; heme binders; resveratrol; zinc compounds; tetrahydropterin analogs, aminoguanidine; and depleters of biopterin, methotrexate, nonsteroidal anti-inflammatory agents, sodium salicylate, and mixtures thereof.

10.. The composition of claim 8, wherein said aminosugar is selected from the group consisting of: glucosamine, glucosamine hydrochloride, glucosamine sulfate, N–acetyl-glucosamine and mixtures thereof.

11.. The composition of claim 8, which optionally contains additional agents selected from the group consisting of: glycosaminoglycans; vitamin A, vitamin B, vitamin C, vitamin E; selenium, silica, manganese, magnesium, copper, boron, analgesics, anti-inflammatory agents, methyl-sulfonyl-methane, S-adenosyl-methionine, alpha-lipoic acid, aloe vera extract, antioxidants, anti-infective agents, adjuvants, anthocyanidins, proanthocyanidins,and herbal derivatives, and mixtures thereof.

12.. The composition of claim 8, optionally uses a controlled release method of an

enteric coating to deliver the composition orally into the gastrointestinal tract.

13.. The composition of claim 8, which further comprises of a pharmaceutically acceptable carrier suitable for oral, rectal, parenteral, intravenous, topical, transdermal, subcutaneous and intramuscular administration.

Applicant respectfully requests that the Examiner elect and take into consideration the preliminary amendment to the claims prior to the initial office action.

Respectfully submitted,

Edward J. Petrus
3413 Spanish Oak Dr.
Austin, Texas 78731
Tel: (512)-454-6500
Fax: (512)-453-0066

Applicant Pro Se

October 7, 2002